- Identification of a novel quinoxaline-based small molecule dual glucagon-like peptide-1 receptor and glucagon receptor allosteric modulator
H. Yeung, K. Barkan, T. Rahman, G. Ladds. Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom,
- Identification of proteomic changes in primary human bronchial epithelial cells in response to chronic formoterol treatment
F. S. Vyas, C. Coveney, D. J. Boocock, C. P. Nelson. Biosciences, Nottingham Trent University, Nottingham, United Kingdom,
- Identification of the first small molecule positive allosteric modulator of the Gastric Inhibitory Polypeptide Receptor
M. Harris, T. Rahman, G. Ladds. Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom,
- Influence of the kinetic profile of labelled ligands on measured binding rates of unlabelled antagonists at the adenosine A3 receptor.
M. Bouzo-Lorenzo1, L. Stoddart1, L. Xia2, A. IJzerman2, L. Heitman2, S. Briddon1, S. Hill1. 1COMPARE & Division of Physiology, Pharmacology and Neuroscience, School of Life Science, Nottingham, United Kingdom, 2Division of Medicinal Chemistry, Leiden Academic Centre for Drug Research, Leiden, Netherlands,
- Investigating the importance of gcgr icl1 region and helix 8 for cell-surface expression and signalling
K. Barkan1, M. Harper1, A. Jazayeri2, D. Poyner3, G. Ladds1. 1Department of Pharmacology, University of Cambridge, Cambridge, United Kingdom, 2Heptares Therapeutics, Heptares Therapeutics, Welwyn Garden City, United Kingdom, 3School of Life and Health Sciences, Aston University, Birmingham, United Kingdom,
- Investigations into novel antagonists of the chemokine receptor CXCR4 to prevent the migration of cancerous cells
I. Hamshaw, M. M. Cominetti, M. Searcey, A. Mueller. Pharmacy, University of East Anglia, Norwich, United Kingdom,
- In vitro characterisation of a M1 muscarinic acetylcholine receptor (mAChR) ligand for positron emission tomography (PET) imaging.
L. Dwomoh1, L. M. Broad2, C. C. Felder3, M. J. Adrian2, S. J. Bradley4, A. B. Tobin5. 1Institute of Molecular, Cell and Systems Biology, University of Glasgow, Glasgow, United Kingdom, 2Neuroscience, Eli Lilly and Co., Surrey, United Kingdom, 3Neuroscience, Eli Lilly and Co., Indianapolis, 4University of Glasgow, Glasgow, United Kingdom, 5University of Glasgow, GLASGOW, United Kingdom,
- Mutation of lysines to arginines in the arrestin N-terminus lowers arrestin affinity to GPCRs by attenuating the release of the arrestin C-terminus
N. M”sslein1, D. Zindel1,2, J. K. S. Tiemann3, M. E. Sommer4, J. Pin2,5, L. Pr‚zeau2,5, P. W. Hildebrand3, M. Bnemann1, C. Krasel1. 1Institute of Pharmacology and Clinical Pharmacy, University of Marburg, Marburg, Germany, 2Institut de G‚nomique Fonctionnelle (IGF), University of Montpellier, Montpellier, France, 3Institute for Medical Physics and Biophysics, University of Leipzig, Leipzig, Germany, 4Institute for Medical Physics and Biophysics, Charit‚ Berlin, Berlin, Germany, 5INSERM U1191, Montpellier, France,
- Novel GRK inhibitors reduce arrestin recruitment to the mu opioid receptor
Y. Alghazwani1, P. Roberts2, K. Antonopoulou2, M. Ostovar2, S. Husbands2, G. Henderson1, E. Kelly1. 1Physiology, Pharmacology & Neuroscience, University of Bristol, Bristol, United Kingdom, 2Department of Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom,
- Pertubation of G-protein coupled receptor-mediated transactivation of ErbB receptor tyrosine kinases by polyamidoamine dendrimer drug delivery systems
S. Akhtar1, B. Chandrasekhar2, A. Z. El-Hashim3, I. F. Benter4. 1Pharmacology, College of Medicine-Qatar University, Doha, Qatar, 2Pharmacology, College of Medicine-KuwaitUniversity, Kuwait, Kuwait, 3Pharmacology, Faculty of Pharmacy-Kuwait University, Kuwait, Kuwait, 4Pharmacology, Faculty of Medicine, Eastern Mediterranean University, Famagusta, North Cyprus, Cyprus,